We investigated the in vitro activity of DS-8587, a novel fluoroquinolone, against Acinetobacter baumannii. The MICs of DS-8587 against clinical isolates and its inhibitory activity against target enzymes were superior to those of ciprofloxacin and levofloxacin. Furthermore, the antibacterial activity of DS-8587 was less affected by adeA/adeB/adeC or abeM efflux pumps than was that of ciprofloxacin and the frequency of single-step mutations with DS-8587 was lower than that with ciprofloxacin. DS-8587 might be an effective agent against A. baumannii infection.
A
cinetobacter baumannii, a Gram-negative coccobacillus, is an increasingly important nosocomial pathogen (1, 2) . A. baumannii infection causes serious clinical problems worldwide, due to an increasing number of A. baumannii clinical isolates becoming resistant to the most commonly clinically utilized antibiotics (3) (4) (5) (6) . Colistin and tigecycline are the last-resort agents to treat multidrug-resistant (MDR) A. baumannii, but unfortunately, strains resistant to these agents have already appeared (7, 8) . Therefore, development of a new treatment option for MDR A. baumannii is an urgent need.
DS-8587 is a novel fluoroquinolone which has potent activity against pathogens that cause community and nosocomial infections (9) . In this study, we assessed the in vitro potency of DS-8587 against A. baumannii.
(Part of this work was presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA [10] .) DS-8587 ( Fig. 1 ) and levofloxacin were synthesized at Daiichi Sankyo, Co., Ltd. Ciprofloxacin, tigecycline, and imipenem were purchased from LKT Laboratories, Inc. (St. Paul, MN). Norfloxacin, amikacin, gentamicin, and chloramphenicol were purchased from Sigma-Aldrich (St. Louis, MO). A. baumannii clinical isolates were collected by the LVFX Surveillance Group in 2007 in Japan (11) . Isolates were confirmed to be A. baumannii by the presence of bla oxa-51-like (12) and sequencing of the 16S-23S rRNA intergenic spacer region (13) . Susceptibility testing was performed by broth microdilution according to the recommended CLSI method (14) .
The antibacterial activities of DS-8587 and reference compounds against clinical isolates of A. baumannii, including quinolone-susceptible isolates and those with mutations in the quinolone resistance-determining regions (QRDRs) of gyrA and parC, are shown in Table 1 . DS-8587 possessed excellent antibacterial activity against wild-type gyrA/parC strains, with MICs of Յ0.015 to 0.06 g/ml. These MICs were 4-to 8-fold and 8-to 16-fold lower than those of levofloxacin and ciprofloxacin, respectively. For clinical isolates with gyrA/parC mutations, the MICs of DS-8587 were 0.5 to 1 g/ml, which were 4-to 16-fold and 64-to 128-fold lower than those of levofloxacin and ciprofloxacin, respectively. The MIC ranges of tigecycline, imipenem, amikacin, and gentamicin for these clinical isolates were 0.12 to 2, 0.12 to 64, 2 to 16, and 1 to Ͼ128 g/ml, respectively. Compared to the reference compounds, DS-8587 exhibited the most potent antibacterial activity against A. baumannii clinical isolates.
To examine the influence of mutations in gyrA on the antibacterial activity of DS-8587, we selected an isogenic mutant of A. baumannii ATCC 19606 (CIP-4) under ciprofloxacin selection pressure. CIP-4 acquired a single mutation in the gyrA QRDR (Ser81Leu) and no mutation in parC. The MIC of DS-8587 against CIP-4 was 1 g/ml, which was 8-fold higher than that for the parent strain (ATCC 19606). In contrast, the corresponding MICs of levofloxacin and ciprofloxacin were 8 and 32 g/ml, which were 16-and 32-fold higher than those against the parent strain, respectively.
To evaluate the inhibitory activity of DS-8587 against wildtype A. baumannii DNA gyrase and topoisomerase IV and altered DNA gyrase and topoisomerase IV, we purified GyrA (wild type and Ser81Leu mutant; position equivalent to Ser83 in Escherichia coli) and GyrB for a supercoiling assay and ParC (wild type and Ser84Leu mutant; position equivalent to Ser80 in E. coli) and ParE for a decatenation assay, respectively (15, 16) . The 50% inhibitory concentrations (IC 50 s) of DS-8587 for wild-type and altered (Ser81Leu in gyrA) DNA gyrase were 3.7-and 7.8-fold lower than those of levofloxacin and 4.9-and 8.4-fold lower than those of ciprofloxacin, respectively ( Table 2 ). The IC 50 s of DS-8587 for wild-type and altered (Ser84Leu in parC) topoisomerase IV were 3.2-and 7.5-fold lower than those of levofloxacin and 2.1-and 5.6-fold lower than those of ciprofloxacin, respectively ( Table 2) .
Efflux-mediated resistance has been reported in A. baumannii (17) . Among those efflux pumps, expression levels of adeA/ adeB/adeC and abeM and corresponding antimicrobial susceptibilities in clinical isolates have been examined (18) (19) (20) (21) . To assess the influence of adeA/adeB/adeC and abeM on the antibacterial activity of DS-8587, we selected two isogenic mutants which overexpressed one of these efflux pumps. The adeA/ adeB/adeC-overexpressing strain (19483 TGC-2) was obtained under the selection pressure of tigecycline (22) . The abeMoverexpressing strain (NFLX-16-2) was obtained under the selection pressure of norfloxacin (21) . In addition, we generated an abeM deletion mutant (2-1-12) from NFLX-16-2 by allelic exchange (23) . As shown by quantitative real-time PCR analysis (primer pairs are shown in Table 3 ) (22), the expression levels of adeB in 19483 TGC-2 and abeM in NFLX-16-2 were 10.2-and 3.4-fold higher than those in the parental strains, 
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In Ϫ8 with DS-8587 and 2.4 ϫ 10 Ϫ6 and 9.6 ϫ 10 Ϫ6 with ciprofloxacin, respectively. The mutant prevention concentration (MPC)/MIC ratios of DS-8587 and ciprofloxacin were 16 to 32 and both 32 for these two strains, respectively.
Our results demonstrate the potent in vitro antibacterial activity of DS-8587 against A. baumannii with excellent inhibitory activity against target enzymes and reduced efflux by adeA/adeB/ adeC and abeM compared with other quinolones tested. These results may explain the lower frequency of single-step mutations with DS-8587 than with ciprofloxacin. These data, taken together with its reported antibacterial activity against MDR A. baumannii (MIC, 0.5 to 1 g/ml) and in vitro bactericidal activity (24) (25) (26) , support the clinical development of DS-8587 to treat infections caused by A. baumannii. 
